79 related articles for article (PubMed ID: 24536061)
1. Molecular precision chemotherapy: overcoming resistance to targeted therapies?
Burdach S
Clin Cancer Res; 2014 Mar; 20(5):1064-6. PubMed ID: 24536061
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
3. Cruel fusion: What a young man's death means for childhood cancer.
Ledford H
Nature; 2017 Mar; 543(7647):608-611. PubMed ID: 28358102
[No Abstract] [Full Text] [Related]
4. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
Tancredi R; Zambelli A; DaPrada GA; Fregoni V; Pavesi L; Riccardi A; Burdach S; Grohar PJ; D'Incalci M
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1317-20. PubMed ID: 25809543
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
[TBL] [Abstract][Full Text] [Related]
8. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Conn E; Hour S; Allegakoen D; Graham G; Petro J; Kouassi-Brou M; Hong SH; Selvanathan S; Çelik H; Toretsky J; Üren A
Mol Med Rep; 2020 Mar; 21(3):1667-1675. PubMed ID: 32016454
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
11. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
12. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
[TBL] [Abstract][Full Text] [Related]
15. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
16. SLFN11: Achilles' Heel or Troublemaker.
Kovar H
Clin Cancer Res; 2015 Sep; 21(18):4033-4. PubMed ID: 26034126
[TBL] [Abstract][Full Text] [Related]
17. Primary Hepatic Ewing Sarcoma With EWS-FLI1 RNA Transcript in a Child.
Pochon C; Martelli H; Mussini C; Pariente D; Heymann MF; Corradini N
J Pediatr Hematol Oncol; 2015 Jul; 37(5):411-3. PubMed ID: 25411865
[No Abstract] [Full Text] [Related]
18. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
[TBL] [Abstract][Full Text] [Related]
19. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors.
Zwerner JP; May WA
Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995
[TBL] [Abstract][Full Text] [Related]
20. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
